Hela Sassi Ouichka, Associate Assistant Practitioner at Gustave Roussy, shared a post on LinkedIn:
“During the American Society of Clinical Oncology (ASCO) 2026, on May 30th, I presented our work entitled:
“cfDNA sequencing as a cutting-edge technology to identify pathogenic germline variants from 8353 patients with advanced tumors at the Gustave Roussy: results from the ORIGAMI study“.
What incredible discussions, during which I had the chance to meet America’s leading experts in precision medicine!
Within the liquid biopsy abstracts, our study was ranked among the 20 top rated abstracts, based on the scientific evaluation performed by the ASCO reviewers. This recognition motivates me to keep contributing to improve cancer care and research.
Stay tuned! The manuscript is ongoing submission!
ASCO26 Top Rated Liquid Biopsy Abstracts
ORIGAMI study: Origin of vaRiants Identified via cfDNA sequencinG:
Actionability in precision Medicine and Incidental findings.”
